“Mixing Triptans”: Patient Satisfaction

Rothrock, John F.; Morey, Veronica

doi:10.1111/j.1526-4610.2010.01819.x

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other strategies involve ''step care within attacks'' [5], whereby a patient would use a simple analgesic initially, but switch to more potent medications later in the same attack, as necessary. Considering that different acute therapies may be needed for effective management in different attacks or within an attack, patients may require access to an array of acute therapies in order to follow a successful management strategy [30,[35][36][37].…”

Section: Discussionmentioning

confidence: 99%

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

Harris

L’Italien

O'Connell³

et al. 2021

Adv Ther

View full text Add to dashboard Cite

Introduction: Migraine is associated with considerable disability for patients not adequately managed with current standards of care. New acute therapies may offer relief for this population of patients; however, population size and associated potential costs of new therapies are unclear. In this study, a conceptual framework was developed to estimate anticipated use of new acute therapies. Methods: Targeted literature review (TLR) was conducted to identify factors affecting access to migraine-specific acute therapies, and characteristics of individuals who would be eligible for new acute therapies. Findings from the TLR were combined to create a framework for estimating the size of the eligible patient population. This framework was used to calculate two estimates of the eligible patient population by applying parameters (i) identified in the TLR and (ii) from a recent budget-impact analysis (BIA). Results: The primary factors affecting access to migraine-specific acute therapies identified in the TLR were consulting a healthcare professional for headache, receiving a migraine diagnosis, and receiving a prescription for migrainespecific treatment. Characteristics of individuals likely to use new acute therapies reflected in the TLR were contraindication to triptans, or failure to respond to/tolerate at least two oral triptans. Application of the framework suggested that 15-25% of individuals with migraine would be eligible for new acute therapies. Conclusion: A limited number of patients currently use migraine-specific acute therapies. Among such patients, a significant proportion do not have adequate symptom control. Accordingly, a minority of individuals with migraine may be expected to use new acute therapies. The framework developed in this study is intended to facilitate estimating the eligible patient population in assessments of costs of new acute therapies. Such assessments should also consider recommendations that patients have access to multiple types of acute therapies, which may yield savings from reduced medication-overuse headache (MOH),

show abstract

Section: Discussionmentioning

confidence: 99%

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

Harris

L’Italien

O'Connell³

et al. 2021

Adv Ther

View full text Add to dashboard Cite

show abstract

“…[12,13] To date, five formulations (conventional and orally disintegrating tablets, subcutaneous injection, nasal spray and rectal suppository) of sumatriptan have been approved; [2,14,15] a sixth (transdermal patch) is currently under regulatory review in the US. [6,11,18,23] According to published reports, [20,24] the level of patient satisfaction with subcutaneous sumatriptan as an initial therapy [20] or as a rescue treatment following the failure of an oral or intranasal dose of sumatriptan [20] (or an oral dose of another triptan [24] ) is high. [19,20] Subcutaneous sumatriptan is the only parenteral formulation of a triptan.…”

Section: Most Common Adverse Events In a Phase IV Study In Patients Wmentioning

confidence: 99%

Needle-Free Subcutaneous Sumatriptan

Frampton

2011

CNS Drugs

View full text Add to dashboard Cite

A needle-free device for delivering a 6 mg fixed dose of sumatriptan into subcutaneous tissues has been developed and approved for the acute treatment of migraine and cluster headache in the US and some EU countries. In a pivotal registration study in healthy adult volunteers, a single dose of needle-free subcutaneous sumatriptan 6 mg demonstrated bioequivalence to a single dose of traditional, needle-based subcutaneous sumatriptan 6 mg when delivered into the abdomen or the thigh, but not the arm. In a noncomparative, multicentre, phase IV study, the administration of (one or two doses of) needle-free subcutaneous sumatriptan 6 mg consistently provided rapid and sustained relief from migraine pain and associated symptoms during the treatment of up to four migraine attacks over a period of up to 60 days among current triptan users. Moreover, the use of needle-free subcutaneous sumatriptan was associated with a significant improvement in treatment satisfaction in these patients who were less than 'very satisfied' with their usual symptomatic therapy. Needle-free subcutaneous sumatriptan was generally well tolerated in the phase IV study. Although the overall adverse event profile of the needle-free delivery system was similar to that previously reported for the needle-based delivery system, it was associated with a numerically higher incidence of administration/injection-site reactions in clinical trials that enrolled healthy adult volunteers.

show abstract

“…In addition, there are high rates of non‐adherence and discontinuation of triptans in those patients prescribed triptans, with at least one third discontinuing triptan use within 1 year . While several studies have investigated patient satisfaction with triptan treatment, barriers to treatment, and predictors of adherence,5,7‐9 little is known about patient satisfaction with triptan education and with their role in decision making when a triptan is prescribed.…”

mentioning

confidence: 99%

Education and Decision Making at the Time of Triptan Prescribing: Patient Expectations vs Actual Practice

et al. 2014

View full text Add to dashboard Cite

Background Optimizing patient satisfaction with their medical care and maximizing patient adherence with treatment plans requires an understanding of patient preferences regarding education and their role in decision making when treatments are prescribed. Objective To assess the congruence between patient expectations and actual practice regarding education and decision making at the time a triptan is prescribed. Methods This multicenter cross-sectional survey was performed by headache fellow members of the American Headache Society Headache Fellows Research Consortium at their respective tertiary care headache clinics. Migraine patients who were new patients to the headache clinic and who were current triptan users (use within prior 3 months and for ≥1 year) or past triptan users (no use within 6 months; prior use within 2 years) completed questionnaires that assessed the education they received and their role in decision making at the time a triptan was first prescribed as well as their desire for education and participation in decision making when a triptan is prescribed. Results Consistent with patient preference, most participants received the majority of their education about the triptan from the prescriber's office (70.2%). In descending rank order, participants most desired to be informed about how to decide if a triptan should be taken, when during the course of migraine a triptan should be taken, possible side effects, cost, and how to obtain refills. Regarding side effects, most participants preferred to receive education about the most common side effects of a triptan rather than addressing all possible side effects. Regarding triptan dosing, participants desired to be informed in descending order of importance about taking other medications with triptans, how many doses can be taken for each migraine, how many doses can be taken each week/month, what to do if the triptan does not work, and the triptan mechanism of action. The vast majority of participants (92%) preferred that the decision to prescribe a triptan be a joint decision between the patient and the provider. In actual practice, participants were not as involved in decision making as they would like to be, with patients reporting that the prescriber was the sole decision maker 55.1% of the time. Participants had confidence in their providers (87.7%) and generally felt they did a good job educating them about the triptan (71.1%). Conclusions Based on this study, it is clear that patients prefer the shared model approach to medical decision making in regards to the prescription of triptans. The majority of patients received education that was generally consistent with their desires. Patients preferred that the prescribing provider be the primary source of information. The most desired educational topics included when/if a triptan should be taken, the number of times a triptan can be taken for a single migraine, co-administration with other acute medications, and the most common side effects. Focusing on these topics should enhance pa...

show abstract

“Mixing Triptans”: Patient Satisfaction

Cited by 5 publications

References 17 publications

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

Needle-Free Subcutaneous Sumatriptan

Education and Decision Making at the Time of Triptan Prescribing: Patient Expectations vs Actual Practice

Contact Info

Product

Resources

About